- Business Wire•10 hours agoFDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA® , the company’s anti-PD-1 therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
- Reuters•10 hours ago
Drug developer Juniper Pharmaceuticals Inc said it would have to restate its financial statements since 2013 due to revenue-recognition errors related to a supply agreement with an affiliate of Germany's Merck KGaA . Juniper also said it was also unable to affirm the full-year forecast for revenue growth in the low- to mid-teen percent range that it had issued in August. Juniper said the errors stemmed from the timing of recording revenue from products sold under a supply agreement with Merck affiliate Ares Trading S.A.
- Investor's Business Daily•11 hours ago
Apple headlines a busy day for earnings, with General Motors, Lockheed Martin, Merck and Edwards Lifesciences among the many notable reports Tuesday. Apple and GM shares are in buy range.
Merck & Co., Inc. (MRK)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||60.99 x 600|
|Ask||61.20 x 200|
|Day's Range||60.63 - 61.48|
|52wk Range||47.97 - 64.86|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||33.32|
|Avg Vol (3m)||10,246,393|
|Dividend & Yield||1.84 (3.01%)|